Anti-fatigue
Agents containing methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol address the unexplored potential of these compounds by acting as anti-fatigue and anti-inflammatory agents, effectively suppressing fatigue markers and modulating immune responses.
Patent Information
- Application Number
- JP2020090212
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-05-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-05-25
AI Technical Summary
Methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol, known primarily for their fragrance uses, have not been explored for their potential anti-fatigue, anti-inflammatory, and immunosuppressive properties.
Development of agents containing methyl dihydrojasmonate and/or 3,7-dimethyl-1,6-octadien-3-ol, which act as thirst suppressants, appetite stimulants, and inhibitors of various biological markers associated with fatigue, inflammation, and immune response, including IL-1β, TNFα, and CD16 expression.
The agents effectively suppress fatigue markers, reduce inflammation, and modulate immune responses, providing relief from fatigue and inflammation by inhibiting key biological markers.
Smart Images

Figure 0007588337000015 
Figure 0007588337000016 
Figure 0007588337000017
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent comprising methyl dihydrojasmonate and / or 3,7-dimethyl-1,6-octadien-3-ol. [Background technology]
[0002] (Linalool) Linalool (IUPAC name: 3,7-dimethyl-1,6-octadien-3-ol) is a type of monoterpene alcohol and is used as a fragrance (Patent Document 1). Linalool is also known to have antioxidant and anti-inflammatory effects.
[0003] (Methyl dihydrojasmonate) Methyl dihydrojasmonate is a volatile organic compound that is used in various developmental pathways such as seed germination, root elongation, flowering, fruit ripening, and senescence, and is also known as a compounding ingredient in fragrances and toiletries (Patent Document 2).
[0004] (Prior literature) Methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol are known to be used in fragrances and the like, but are not known to be used in the context of the present invention. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2020-012022 A [Patent Document 2] JP 2018-203628 A Summary of the Invention [Problem to be solved by the invention]
[0006] The objective of the present invention is to find a new use for methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol, which are conventionally known as fragrances, and to provide a new agent containing the fragrance of the present invention (methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol). [Means for solving the problem]
[0007] The present inventors exposed fatigue model rats to methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol and measured each marker in the rats, thereby discovering new uses of the fragrances according to the present invention and completing the present invention.
[0008] That is, the present invention includes the following. 1. Any one of the following agents 1) to 20) containing methyl dihydrojasmonate. 1) Thirst suppressants or water intake suppressants 2) BAP increase inhibitors or BAP inhibitors 3) CD14 expression regulators and CD14 expression inhibitors 4) CD16 expression regulators and CD16 expression inhibitors 5) Appetite stimulants or weight loss suppressants 6) d-ROMs increase inhibitors or d-ROMs inhibitors 7) Adrenaline increase inhibitors or adrenergic suppressants 8) Noradrenaline increase inhibitors or noradrenaline inhibitors 9) Dopamine increase inhibitors or dopamine inhibitors 10) IL-1β increase inhibitor or IL-1β inhibitor 11) IL-2 suppressant or IL-2 promoter 12) IL-10 increase inhibitor or IL-10 inhibitor 13) IL-5 decrease inhibitor or IL-5 promoter 14) IL-17A decrease inhibitor or IL-17A promoter 15) IL-6 expression promoter or IL-6 expressing agent 16) TNFα increase inhibitor or TNFα inhibitor 17) Fatigue inhibitors 18) Stress suppressants 19) Inflammatory suppressants 20) Immunosuppressants 2. Any one of the following agents 1) to 20) containing 3,7-dimethyl-1,6-octadien-3-ol. 1) Thirst suppressants or water intake suppressants 2) BAP increase inhibitors or BAP inhibitors 3) CD14 expression regulators and CD14 expression inhibitors 4) CD16 expression regulators and CD16 expression inhibitors 5) Appetite stimulants or weight loss suppressants 6) d-ROMs increase inhibitors or d-ROMs inhibitors 7) Adrenaline increase inhibitors or adrenergic suppressants 8) Noradrenaline increase inhibitors or noradrenaline inhibitors 9) Dopamine increase inhibitors or dopamine inhibitors 10) IL-1β increase inhibitor or IL-1β inhibitor 11) IL-2 suppressant or IL-2 promoter 12) IL-10 increase inhibitor or IL-10 inhibitor 13) IL-5 decrease inhibitor or IL-5 promoter 14) IL-17A decrease inhibitor or IL-17A promoter 15) IL-6 expression promoter or IL-6 expressing agent 16) TNFα increase inhibitor or TNFα inhibitor 17) Fatigue inhibitors 18) Stress suppressants 19) Inflammatory suppressants 20) Immunosuppressants 3. A thirst suppressant or water intake suppressant comprising methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol. 4. A BAP increase inhibitor or a BAP inhibitor, comprising methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol. 5. A CD14 expression regulator and a CD14 expression inhibitor, comprising methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol. 6. A CD16 expression regulator and a CD16 expression inhibitor, comprising methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol. 7. A method for determining or assisting in the determination of fatigue level, which comprises measuring 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the following markers: Body weight, dopamine, adrenaline, noradrenaline, d-ROMs, BAP, IL-1β, TNFα, CD14, CD16, IL-2, IL-5, IL-6, IL-10, IL-17A 8. A method for determining or assisting in the determination of fatigue level, which comprises measuring 1, 2, 3, 4, 5, 6, 7 or 8 of the following markers: Dopamine, IL-1β, TNFα, d-ROMs, BAP, IL-2, IL-5, IL-10 9. A method for determining or assisting in the determination of fatigue level, which comprises measuring one, two, three, four, five or six of the following markers: Dopamine, IL-1β, d-ROMs, BAP, IL-2, IL-5 10. A method for determining or assisting in the determination of inflammation level, which comprises measuring one, two, three, four or five of the following markers: IL-1β, TNFα, IL-10, CD14, CD16 11. A method for determining or assisting in the determination of neurological abnormalities, endocrine abnormalities, high oxidative stress, or abnormal immune development, which comprises measuring one, two, three, four, or five of the following markers: IL-1β, TNFα, IL-10, CD14, CD16 Effect of the Invention
[0009] The present invention could provide a novel agent containing methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol. [Brief description of the drawings]
[0010] [Figure 1]Conceptual diagram of a fragrance exposure box. [Diagram 2] Overview of fragrance exposure. [Diagram 3] Body weight measurement results. The vertical axis shows the average body weight (g) in each group. [Figure 4] Results of serum d-ROMs test. The vertical axis indicates the mean serum d-ROMs (U.CARR) level in each group. [Diagram 5] Results of the BAP test. The vertical axis shows the average serum BAP concentration in each group. [Figure 6] Results of plasma adrenaline measurement of catecholamines. The vertical axis shows the average plasma adrenaline concentration in each group. [Figure 7] Results of plasma noradrenaline measurement of catecholamines. The vertical axis shows the average plasma noradrenaline concentration in each group. [Figure 8] Results of plasma dopamine measurement of catecholamines. The vertical axis shows the average plasma dopamine concentration in each group. [Figure 9] Left: Results of principal component analysis of d-ROMs and BAP. Right: Results of extraction of principal components of d-ROMs and BAP. "no" indicates no load, and "FT" indicates load. [Figure 10] Results of Pearson correlation analysis of five fatigue indices. [Figure 11] Left: Results of principal component analysis of dopamine, d-ROMs, and BAP. Right: Results of extraction of principal components of dopamine, d-ROMs, and BAP. PC1 indicates the first principal component. FTG indicates the condition with load. [Figure 12] Measurement results of serum cytokine (IL-1β, IL-2, IL-10, IL-5, and IL-17A) concentrations. FTG indicates loading. [Figure 13] Analysis results of correlation of serum cytokine concentrations. Upper left and lower figures: Correlation plot of serum cytokine concentrations. The units of values are the same as in Figure 12. Upper right figure: Correlation analysis results. [Figure 14]Top left: Results of principal component analysis of serum cytokines (IL-1β, IL-2, IL-10, IL-5, and IL-17A). Bottom left: Factor loading plot. The horizontal axis shows the factor loading of PC1, and the vertical axis shows the factor loading of PC2. Top right: Score of principal component PC1 of serum cytokines. Bottom right: Score of principal component PC2 of serum cytokines. PC1 shows the first principal component, and PC2 shows the second principal component. FTG shows loading. [Figure 15] Measurement results of IL-1β mRNA expression in white blood cells. The vertical axis shows the average relative expression, with the expression of sample number 1 (without load and no fragrance exposure) in each group (three samples were obtained for each condition) taken as 1. [Figure 16] Measurement results of IL-6 mRNA expression in white blood cells. The vertical axis shows the average relative expression, with the expression of sample number 1 (without load and no fragrance exposure) in each group (three samples were obtained for each condition) taken as 1. [Figure 17] Measurement results of TNFα mRNA expression in white blood cells. The vertical axis shows the average relative expression, with the expression of sample number 1 (without load and no fragrance exposure) in each group (three samples were obtained for each condition) taken as 1. [Figure 18] Measurement results of CD14 mRNA expression in leukocytes. The vertical axis shows the average relative expression, with the expression of sample number 1 (without load and no fragrance exposure) in each group (three samples were obtained for each condition) taken as 1. [Figure 19] Measurement results of CD16 mRNA expression in leukocytes. The vertical axis shows the average relative expression, with the expression of sample number 1 (without load and no fragrance exposure) in each group (three samples were obtained for each condition) taken as 1. [Figure 20]Upper left: Results of a comprehensive principal component analysis of 10 factors, including three fatigue factors (dopamine, d-ROMs, BAP) and five serum cytokine factors (IL-1β, IL-10, IL-2, IL-5, IL-17A), plus two factors in leukocytes, IL-1β mRNA and TNFα mRNA, which showed a tendency to decrease with fragrance exposure. Lower left: Factor loading plot. The horizontal axis shows the factor loading of PC1, and the vertical axis shows the factor loading of PC2. Upper right: Scores of the principal component PC1 of the 10 factors. Lower right: Scores of the principal components PC2 (left side) and PC3 (right side) of serum cytokines. PC1 shows the first principal component, PC2 shows the second principal component, and PC3 shows the third principal component. FTG indicates there is a load. [Figure 21] Top left: Results of principal component analysis using 16 factors (left side) and score of 16-factor principal component PC1 (right side). Bottom left: Results of cluster analysis. Control indicates no load, fatigue indicates load. Top right: Results of principal component analysis using 8 factors. Bottom right: Score of 8-factor principal component PC1. [Figure 22] Measurement results of water intake. The vertical axis shows the average amount of water intake in each group. [Figure 23] Measurement results of IL-1β mRNA expression in white blood cells. The vertical axis shows the average relative expression, with the expression of sample number 0 (no load or fragrance exposure) in each group (4-5 samples were obtained for each condition) taken as 1. [Figure 24] Left: Results of comprehensive principal component analysis of nine factors: dopamine, IL-1β mRNA, TNFα mRNA, d-ROMs, BAP, IL-2, IL-5, IL-1β, and IL-10. Right: Scores of principal component PC1 of the nine factors. PC1 is the first principal component, PC2 is the second principal component, and PC3 is the third principal component. FTG indicates the presence of a load. [Diagram 25] Left: Results of comprehensive principal component analysis of six factors: dopamine, IL-1β mRNA, d-ROMs, BAP, IL-2, and IL-5. Right: Scores of the principal component PC1 of the six factors. PC1 indicates the first principal component, and PC2 indicates the second principal component. FTG indicates the presence of a load. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] (Agent of the present invention) The agent of the present invention is intended for the following: The following agents contain methyl dihydrojasmonate, and particularly relate to agents for use during fatigue, stress, inflammation, abnormal immune development, and sleep. Thirst suppressants or water intake suppressants. * Appetite stimulants or weight loss suppressants. - d-ROMs increase inhibitors or d-ROMs inhibitors. - BAP increase inhibitor or BAP inhibitor. - Adrenaline increase inhibitors or adrenaline suppressants. -Noradrenaline increase inhibitors or noradrenaline inhibitors. -Dopamine increase inhibitors or dopamine suppressants. 〇IL-1β increase inhibitor or IL-1β inhibitor. - IL-2 decrease inhibitor or IL-2 promoter. - IL-10 increase inhibitor or IL-10 inhibitor. - IL-5 decrease inhibitor or IL-5 promoter. - IL-17A decrease inhibitor or IL-17A promoter. 〇IL-6 expression promoter or IL-6 expressing agent. -TNFα increase inhibitor or TNFα inhibitor. - CD14 expression regulators and CD14 expression inhibitors. -CD16 expression regulators and CD16 expression inhibitors. 〇 Fatigue inhibitor. 〇Stress suppressant. 〇Inflammatory suppressant. 〇Immunosuppressants.
[0012] The following agents containing 3,7-dimethyl-1,6-octadien-3-ol, particularly for use during fatigue, stress, inflammation, abnormal immune development, and sleep: Thirst suppressants or water intake suppressants. * Appetite stimulants or weight loss suppressants. - d-ROMs increase inhibitors or d-ROMs inhibitors. - BAP increase inhibitor or BAP inhibitor. - Adrenaline increase inhibitors or adrenaline suppressants. -Noradrenaline increase inhibitors or noradrenaline inhibitors. -Dopamine increase inhibitors or dopamine suppressants. 〇IL-1β increase inhibitor or IL-1β inhibitor. - IL-2 decrease inhibitor or IL-2 promoter. - IL-10 increase inhibitor or IL-10 inhibitor. - IL-5 decrease inhibitor or IL-5 promoter. - IL-17A decrease inhibitor or IL-17A promoter. 〇IL-6 expression promoter or IL-6 expressing agent. -TNFα increase inhibitor or TNFα inhibitor. - CD14 expression regulators and CD14 expression inhibitors. -CD16 expression regulators and CD16 expression inhibitors. 〇 Fatigue inhibitor. 〇Stress suppressant. 〇Inflammatory suppressant. 〇Immunosuppressants.
[0013] (How to assess fatigue level) The method for determining fatigue level of the present invention measures the following 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 markers. Body weight, dopamine, adrenaline, noradrenaline, d-ROMs, BAP, IL-1β, TNFα, CD14, CD16, IL-2, IL-5, IL-6, IL-10, IL-17A The method of the present invention for assessing fatigue level preferably measures one, two, three, four, five, six, seven or eight of the following markers: Dopamine, IL-1β, TNFα, d-ROMs, BAP, IL-2, IL-5, IL-10 More preferably, the method of the present invention for assessing fatigue level comprises measuring one, two, three, four, five or six of the following markers: Dopamine, IL-1β, d-ROMs, BAP, IL-2, IL-5 In the method of the present invention, the object to be measured is not limited, and may be any of mRNA, cDNA, protein, and the like.
[0014] (Method of determining the degree of inflammation) The method of the present invention for determining the degree of inflammation measures one, two, three, four or five of the following markers: IL-1β, TNFα, IL-10, CD14, CD16
[0015] (Method for determining neurological abnormalities, endocrine abnormalities, high oxidative stress, and abnormal immune development) The method of the present invention for determining neurological abnormalities, endocrine abnormalities, high oxidative stress, and abnormal immune development measures one, two, three, four, or five of the following markers: IL-1β, TNFα, IL-10, CD14, CD16
[0016] (Agent of the present invention) Each agent of the present invention contains, as an active ingredient, methyl dihydrojasmonate and / or 3,7-dimethyl-1,6-octadien-3-ol (LINALOOL), which are known as fragrances. Methyl dihydrojasmonate is manufactured by Zeon Corporation under the trade name CLAIGEON TM It is sold as. 3,7-Dimethyl-1,6-octadien-3-ol is commercially available from Tokyo Chemical Industry Co., Ltd. and the like.
[0017] (Form of the agent of the present invention) The flavors according to the present invention may be used alone or in combination with one another, and may also be combined with other flavors. Other fragrances include aldehydes, phenols, alcohols, ethers, esters, hydrocarbons, ketones, lactones, musks, fragrances having a terpene skeleton, natural fragrances, natural essential oils, plant extracts, animal fragrances, etc. In addition, for example, fragrances described in "Japan Patent Office, Collection of Well-Known and Commonly Used Techniques (Fragrances), Part III, Cosmetic Fragrances, p. 26-103, published June 15, 2001" and the like can be mentioned. Specific examples thereof include hydrocarbons such as limonene, α-pinene, β-pinene, terpinene, cedrene, longifolene, and valencene; citronellol, geraniol, nerol, terpineol, dihydromyrcenol, ethyl linalool, farnesol, nerolidol, cis-3-hexenol, cedrol, menthol, borneol, β-phenylethyl alcohol, benzyl alcohol, phenylhexanol, 2,2,6-trimethylcyclohexyl-3-hexanol, 1-(2-t-butylcyclohexyloxy)-2-methylcyclohexyl, 1-(2-methyl ... -butanol, 4-isopropylcyclohexanemethanol, 4-methyl-2-(2-methylpropyl)tetrahydro-2H-pyran-4-ol, 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, isocamphylcyclohexanol, 3,7-dimethyl-7-methoxyoctan-2-ol, and other alcohols; phenols such as eugenol, thymol, and vanillin;Linalyl formate, citronellyl formate, geranyl formate, n-hexyl acetate, cis-3-hexenyl acetate, linalyl acetate, citronellyl acetate, geranyl acetate, neryl acetate, terpinyl acetate, nopyr acetate, bornyl acetate, isobornyl acetate, ot-butylcyclohexyl acetate, pt-butylcyclohexyl acetate, tricyclodecenyl acetate, benzyl acetate, styraryl acetate, cinnamyl acetate, dimethicone ethyl benzyl carbinyl acetate, 3-pentyl tetrahydropyran-4-yl acetate, citronellyl propionate, tricyclodecenyl propionate, allyl cyclohexyl propionate, ethyl 2-cyclohexyl propionate, benzyl propionate, citronellyl butyrate, dimethyl benzyl carbinyl n-butyrate, tricyclodecenyl isobutyrate, methyl 2-nonenoate, methyl benzoate, benzyl benzoate, methyl cinnamate, methyl salicylate, n-hexyl Esters such as silsalicylate, cis-3-hexenyl salicylate, geranyl tiglate, cis-3-hexenyl tiglate, methyl jasmonate, methyl-2,4-dihydroxy-3,6-dimethylbenzoate, ethyl methylphenylglycidate, methyl anthranilate, and flutate; n-octanal, n-decanal, n-dodecanal, 2-methylundecanal, 10-undecenal, citronellal, citral, hydroxycitronellal, and dimethyltetrahydrobenzaldehyde. aldehydes such as 4(3)-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carbaldehyde, 2-cyclohexylpropanal, p-butyl-α-methylhydrocinnamic aldehyde, p-isopropyl-α-methylhydrocinnamic aldehyde, p-ethyl-α,α-dimethylhydrocinnamic aldehyde, α-amylcinnamic aldehyde, α-hexylcinnamic aldehyde, piperonal, and α-methyl-3,4-methylenedioxyhydrocinnamic aldehyde;Methylheptenone, 4-methylene-3,5,6,6-tetramethyl-2-heptanone, amylcyclopentanone, 3-methyl-2-(cis-2-penten-1-yl)-2-cyclopenten-1-one, methylcyclopentenolone, rose ketone, γ-methylionone, α-ionone, carvone, menthone, camphor, nootkatone, benzylacetone, anisylacetone, methyl β-naphthyl ketone, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, maltose Ketones such as 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethylnaphthalene, muscone, civetone, cyclopentadecanone, and cyclohexadecenone; acetals and ketals such as acetaldehyde ethyl phenylpropyl acetal, citral diethyl acetal, phenylacetaldehyde glycerin acetal, cis-3-hexenal diethyl acetal, and ethyl acetoacetate ethylene glycol ketals. ethers such as anethole, β-naphthyl methyl ether, β-naphthyl ethyl ether, limonene oxide, rose oxide, 1,8-cineole, racemic or optically active dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan; nitriles such as citronellyl nitrile; γ-nonalactone, γ-undecalactone, σ-decalactone, γ-jasmolactone, coumarin, cyclopentadecanolide, cyclohexadecanolide, ambu lactones such as ethyl ethoxide, ethylene brassillate, and 11-oxahexadecanolide; natural essential oils and natural extracts such as orange, lemon, bergamot, mandarin, peppermint, spearmint, lavender, chamomile, rosemary, eucalyptus, sage, basil, rose, geranium, jasmine, ylang-ylang, anise, clove, ginger, nutmeg, cardamom, cedar, cypress, vetiver, patchouli, and labdanum, but are not limited thereto; In addition, the fragrance of the present invention may be diluted with a suitable solvent (water, oils and fats, or organic solvents. Examples of organic solvents include, but are not limited to, triethyl citrate, dipropylene glycol, ethanol, isopropanol, benzyl benzoate, isopropyl myristate, diethyl phthalate, liquid paraffin, glycerin, and propylene glycol). In addition, examples of the agent of the present invention include a liquid composition (particularly, a flavor) containing the fragrance of the present invention, a solid composition (particularly, a powder) containing the fragrance of the present invention, and a volatile composition containing the fragrance of the present invention. The fragrance of the present invention may be used, if necessary, by being supported on various fibers (cloth, nonwoven fabric), natural polymers, porous substances, gels, resins, wax, ceramics, wood, clay substances, lotions, emulsions, creams, ointments, patches, etc.
[0018] The content of the flavor in the agent of the present invention can be appropriately changed depending on the purpose of use. In particular, the content of the flavor in the present invention is preferably an amount that can obtain the effect of the agent of the present invention by inhalation. The amount of the fragrance to be added to the total amount may be appropriately determined in consideration of the purpose of use, etc., and may be an amount that is sufficient to obtain the effect by inhalation, transdermal, oral administration, etc., and varies depending on the form of use and the selected fragrance. In particular, the content of the fragrance in the present invention is preferably an amount that can obtain the effect of the agent of the present invention by inhalation, transdermal, or oral administration, and the amount of the fragrance to be added to the total amount may be, for example, 0.001 to 50%, or 0.01 to 30%.
[0019] The agent of the present invention may be contained in a food or drink. Examples of the food or drink include beverages such as tea, juice, non-alcoholic beer, beer, happoshu, whiskey, and liqueur, as well as foods such as rice, rice porridge, bread, ramen, pasta, udon, somen, pizza, naan, and baked goods, but are not limited thereto.
[0020] The agent of the present invention may be included in cosmetics. Examples of cosmetics include fragrance cosmetics such as perfume, eau de parfum, eau de toilette, and cologne, hair cosmetics such as shampoo, rinse, hair treatment, hair styling foam, hair styling spray, hair styling gel, hair cologne, hair coloring agent for gray or black hair, and hair remover, basic cosmetics for the human body such as skin lotion, skin milk, skin cream, and sunscreen, various makeup cosmetics such as powder foundation, liquid foundation, mascara, eyeliner, lipstick, lip gloss, lip cream, and nail color, body cosmetics such as body cream, body milk, body lotion, body powder, soap, body shampoo, powdered bath agent, liquid bath agent, deodorant, antiperspirant, and sunscreen, and cosmetics for the oral cavity.
[0021] The agent of the present invention may be included in a pharmaceutical or quasi-drug. As a pharmaceutical or quasi-drug, a dosage form suitable for oral or transdermal absorption is preferable because of its mild action, and examples of the dosage forms include liquids, powders, powders, granules, tablets, sugar-coated tablets, capsules, suspensions, suppositories, bath agents, ointments, creams, gels, patches, injections, and eye drops. The agent of the present invention may be contained in health and sanitary materials, such as clean tissue, masks, bandages, gauze, bandages, cleansing cotton, etc.
[0022] (Target of administration) The subjects to which the agents of the present invention are administered include mammals inclusively, including, but not limited to, humans, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, and monkeys. For example, when the agent of the present invention is used for humans, the concentration of the volatilized fragrance of the present invention is not particularly limited as long as the effect of the agent of the present invention can be obtained. 3 , preferably 0.01 to 10 mg / m 3 It is preferable to take it through the nose, mouth, skin, etc. It is also preferable to take 0.1 mg to 50 mg per hour.
[0023] (Method of producing the agent of the present invention) There are no particular limitations on the method for producing methyl dihydrojasmonate and 3,7-dimethyl-1,6-octadien-3-ol, and they may be synthesized, extracted from natural products, or commercially available products. Depending on the application of the agent of the present invention to foods and beverages, cosmetics, pharmaceuticals, quasi-drugs, health and hygiene materials, etc., methods include mixing it with other fragrances and diluting it with a solvent such as water or ethanol, emulsifying it together with a surfactant, or mixing it with an excipient and then powdering it.
[0024] (Thirst suppressant) The thirst suppressant or water intake suppressant of the present invention can suppress water intake, which means, for example, suppressing water intake to 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less, assuming that the original amount of water intake when fatigued is 100.
[0025] (Appetite stimulant and appetite stimulant for fatigue) The appetite enhancer or weight loss suppressor of the present invention can suppress weight loss, particularly weight loss during fatigue. For example, this means suppressing weight loss to 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less, assuming that the original weight loss during fatigue is 100.
[0026] (Growth inhibitor) Each increase inhibitor of the present invention can inhibit an increase in mRNA and / or protein, preferably leukocyte mRNA and / or serum protein, of IL-1β, IL-10, TNFα, CD14, and / or CD16. For example, when the increase in the expression level of mRNA and / or protein during fatigue is taken as 100, it means that the increase in the expression level of mRNA and / or protein is inhibited to 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less.
[0027] (Decrease inhibitor) Each of the decrease inhibitors of the present invention can inhibit the decrease in mRNA and / or protein, preferably leukocyte mRNA and / or serum protein, of IL-2, IL-5 and / or IL-17A. For example, when the decrease in the expression level of mRNA and / or protein during fatigue is taken as 100, it means that the decrease in the expression level of mRNA and / or protein is inhibited to 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less.
[0028] (IL-6 expression promoter) The IL-6 expression promoter of the present invention can promote the expression of IL-6 mRNA and / or protein, preferably the protein in serum. For example, this means promoting the expression level of mRNA and / or protein to 110% or more, 120% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more, assuming that the expression level of original mRNA and / or protein is 100.
[0029] (CD14 expression regulator) The CD14 expression regulator of the present invention can regulate the expression of CD14 mRNA and / or protein, preferably leukocyte mRNA. For example, when the expression level of mRNA and / or protein under normal circumstances is taken as 100, it means maintaining or increasing the expression level of mRNA and / or protein to 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, 110% or more, 120% or more, 130% or more, 140% or more, 150% or more, 160% or more, 170% or more, 180% or more, 190% or more, or 200% or more, and when the increase in the expression level of mRNA and / or protein under normal fatigue is taken as 100, it means suppressing the increase in the expression level of mRNA and / or protein to 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, or 1% or less.
[0030] (CD16 expression regulator) The CD16 expression regulator of the present invention can regulate the expression of CD16 mRNA and / or protein, preferably leukocyte mRNA, and can maintain the expression state under normal conditions and suppress its increase under fatigue conditions.
[0031] (Judgment method) The steps of the method of determining a level of fatigue, the method of determining a level of inflammation, and the method of determining neurological abnormalities, endocrine abnormalities, high oxidative stress, and abnormal immune development of the present invention can be exemplified as follows, but are not particularly limited thereto. (1) Obtaining a biological sample from a subject (preferably at a time of fatigue). (2) A step of performing mRNA expression analysis, protein expression analysis (cytokine concentration measurement), and / or catecholamine measurement in the biological sample obtained in the step (1). (3) Measuring the subject's weight. (4) A step of comparing the measurement result of the subject with a cutoff value or the measurement result of the subject under normal circumstances.
[0032] (Biological samples) In the present specification, the "biological sample" is not particularly limited as long as it allows for mRNA expression analysis, protein expression (cytokine concentration) analysis and / or catecholamine measurement, and examples thereof include tissues, cells, body fluids, urine, and mixtures thereof isolated from subjects, or nucleic acid extracts prepared from the mixtures. The nucleic acid extract preferably contains genomic DNA. The nucleic acid extract can be prepared by extracting nucleic acid according to a known nucleic acid preparation method. Here, examples of body fluids include blood, lymph, and tissue fluids (interstitial fluid, intercellular fluid, interstitial fluid). A preferred example is blood isolated from a subject. For mRNA expression analysis, a leukocyte fraction is more preferred, for protein expression analysis, a serum fraction is more preferred, and for catecholamine measurement, a plasma fraction is more preferred.
[0033] (Cutoff value of the present invention) In the present invention, the "cutoff value of each measurement target (marker) in a biological sample derived from a subject" can be set in advance. The "cutoff value of each measurement target (marker) in a biological sample derived from a subject" can be calculated from the average value of each measurement target (marker) in a biological sample derived from a subject with fatigue, the average value of each measurement target (marker) in a biological sample derived from a subject with inflammation, the average value of each measurement target (marker) in a biological sample derived from a subject with neurological abnormality, endocrine abnormality, high oxidative stress, and abnormal immune development, or the average value of each measurement target (marker) in a biological sample derived from a healthy subject. The cut-off value is set by calculating from the above-mentioned average values and / or the average values of the measurement targets (markers) in biological samples from healthy subjects. Usually, a value equal to or higher than a preset cut-off value (further, within ±70% of the standard deviation, within ±50% of the standard deviation, within ±30% of the standard deviation, within ±20% of the standard deviation, or within ±50% of the standard deviation) can be determined as positive. As another method for setting the cutoff value, a receiver operating characteristic (ROC) curve can be created using commercially available statistical analysis software to determine optimal sensitivity and specificity.
[0034] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these. EXAMPLES
[0035] (Evaluation of the anti-fatigue effect of fragrance substances) The anti-fatigue effects of fragrance exposure were evaluated by exposing fatigue model rats to fragrance substances and measuring fatigue markers.Fatigue markers were evaluated, including body weight, serum d-ROMs / BAP, plasma catecholamines (adrenaline, noradrenaline, dopamine), leukocyte mRNA expression (IL-1β, TNFα, CD14, CD16), and serum protein expression (Luminex).
[0036] (Laboratory animals and fragrances used) Eighteen 7-week-old male Sprague-Dawley rats (9 without fatigue [3 each of no fragrance, exposure to LINALOOL, and exposure to CLAIGEON], and 9 with fatigue [3 each of no fragrance, exposure to LINALOOL, and exposure to CLAIGEON]) were used.
[0037] (Measurement items) Body weight, serum d-ROMs / BAP, plasma catecholamines (adrenaline, noradrenaline, dopamine), leukocyte mRNA expression (IL-1β, TNFα, CD14, CD16, IL-6, TGFβ), serum protein expression (Luminex)
[0038] (Test group) The following groups were tested: No water immersion stress / no fragrance group No water immersion stress / LINALOOL exposure group No water immersion stress / CLAIGEON exposure group Water immersion stress / no fragrance group Water immersion stress / LINALOOL exposure group Water immersion stress / CLAIGEON exposure group
[0039] (Fragrance exposure) The fragrances used were CLAIGEON (methyl dihydrojasmonate) or LINALOOL (3,7-dimethyl-1,6-octadien-3-ol). For the rats in the fragrance group, 1 g of 100% CLAIGEON or 100% LINALOOL was weighed out and soaked into filter paper, which was then placed on a glass petri dish, and the glass petri dish was then placed in a corner of the fragrance exposure box shown in Figure 1. The fragrance exposure box had air holes only on the front and back, and the air holes on the sides were blocked with tape (the air holes on the sides were opened if the rats appeared to be having difficulty breathing). The fragrance exposure was for 24 hours. Rats in the fragrance-free group were housed for 24 hours in a box under the same conditions except that it did not contain the glass dish containing the fragrance.
[0040] (Fatigue Loading and Sample Collection Method) The rats in the water-immersion stress group were housed in a cage submerged in water at 1.5 cm (23°C) for 24 hours to deprive them of rest and sleep, while the rats in the non-water-immersion stress group were housed in a cage at 23°C for 24 hours. The rats were housed one per cage. They were allowed to drink water and eat food ad libitum during the feeding period (Fig. 1, Fig. 2). The rats' weights were measured over time (0 and 24 hours). 24 hours after the start of the load, the rats were anesthetized with 4% sevoflurane, and cardiac blood samples and organ samples (spleen and liver) were taken.
[0041] (Sample separation) After water immersion stress, blood was collected from each rat, and leukocytes, serum, and plasma were separated. White blood cells were prepared by mixing 2 mL of blood (containing 5 mM EDTA) with an aqueous dextran solution (final concentration 1.5%), precipitating the red blood cell components, collecting the white blood cell fraction from the supernatant, and removing excess red blood cells by hemolysis to obtain the white blood cell sample. After that, first strand DNA was prepared and then frozen and stored. Plasma was prepared by centrifuging 2 mL of blood (containing 5 mM EDTA) at 3000 rpm for 10 minutes at room temperature, and the supernatant was used as plasma. It was immediately frozen at -70°C. After collecting approximately 5 mL of blood (without EDTA), serum was left to stand for 30 minutes or more (within 100 minutes) to allow blood coagulation and fibrinolysis, and then centrifuged twice at 3,000 rpm for 10 minutes at room temperature, and the supernatant was collected.
[0042] (d-ROMs test and BAP test) The frozen serum from each group was shipped in a box containing dry ice and entrusted to the Japan Institute of Aging Control, Nikken Seiru Co., Ltd.
[0043] (Catecholamine measurement) Frozen plasma from each group was delivered, and measurements of three catecholamine fractions (adrenaline, noradrenaline, and dopamine) were outsourced to SRL.
[0044] (Serum cytokine concentrations) The separated serum was used to quantify the expressed proteins in the serum. Frozen stocks were thawed on ice, and 10 μL of each serum was used per well. Using the Multiplex Rat Cytokine Panel Select Kit (Merck), 10 types of rat cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17A, IFNγ, and TNFα) were measured using a Luminex 200 detector (Merck).
[0045] (Real-time PCR) Total RNA was isolated from white blood cells using an RNeasy kit (QIAGEN). First strand DNA was synthesized from the isolated RNA using a Ready-to-GO You prime kit (GE Healthcare) and frozen and stored at -30°C. The following day, real-time PCR was performed using SYBRgreen mix (Thermo Fisher Scientific). The instrument used was a Step OnePlus (Thermo Fisher Scientific). The primers used are shown in Table 1.
[0046] [Table 1]
[0047] (result) body weight The results are shown in Tables 2 and 3 and in FIG. Regarding body weight, the non-loaded group showed a tendency for weight to increase, while the loaded group showed a clear tendency for weight to decrease. The unchallenged / LINALOOL-exposed group gained weight compared to the unchallenged / no fragrance group. Weight loss was reduced in the challenged / CLAIGEON-exposed group compared with the challenged / no-fragrance group (Figure 3). Regarding body weight, the non-loaded group showed a tendency to gain weight, while the loaded group showed a clear tendency to lose weight. Weight loss was suppressed in the load-exposed CLAIGEON group compared to the fragrance-free group. Therefore, the appetite-increasing effect (weight loss-inhibiting effect) and appetite-increasing effect during fatigue (weight loss-inhibiting effect during fatigue) of LINALOOL and CLAIGEON were confirmed.
[0048] [Table 2]
[0049] [Table 3]
[0050] d-ROMs The results are shown in Table 4 and FIG. In the loaded group, a tendency for suppression was observed in the LINALOOL and CLAIGEON groups. Thus, the inhibitory effect of LINALOOL and CLAIGEON on increases in d-ROMs (dROMs) was confirmed.
[0051] [Table 4]
[0052] BAP The results are shown in Table 4 and FIG. The water immersion stress / no fragrance group had increased serum BAP concentrations compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had lower serum BAP concentrations compared to the fragrance-free group. The LINALOOL exposure group and the CLAIGEON exposure group each suppressed the increase in serum BAP concentration in the loaded group relative to the unloaded group, compared to the fragrance-free group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on the increase in BAP was confirmed.
[0053] Adrenaline The results are shown in Table 5 and FIG. The water immersion stress / no fragrance group had increased plasma adrenaline concentrations compared to the no water immersion stress / no fragrance group. The LINALOOL exposure group and the CLAIGEON exposure group each suppressed the increase in plasma adrenaline concentration in the loaded group relative to the unloaded group, compared to the fragrance-free group. Therefore, the effect of LINALOOL and CLAIGEON in suppressing an increase in adrenaline was confirmed.
[0054] [Table 5] Ad: Adrenaline, Nor: Noradrenaline, Dopa: Dopamine
[0055] Norepinephrine The results are shown in Table 5 and FIG. The water immersion stress / no fragrance group had increased plasma noradrenaline concentrations compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had lower plasma noradrenaline concentrations compared to the no-fragrance group. The LINALOOL exposure group and the CLAIGEON exposure group each suppressed the increase in plasma noradrenaline concentration in the loaded group relative to the unloaded group, compared to the no-flavoring group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on the increase in noradrenaline was confirmed.
[0056] Dopamine The results are shown in Table 5 and FIG. The water immersion stress / no fragrance group had increased plasma dopamine concentrations compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had lower plasma dopamine concentrations compared to the fragrance-free group. The LINALOOL exposure group and the CLAIGEON exposure group each suppressed the increase in plasma dopamine concentration in the loaded group relative to the unloaded group, compared to the fragrance-free group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on dopamine increase was confirmed.
[0057] (Analysis of five fatigue indicators) Principal component analysis of d-ROMs and BAP enabled extraction of the principal component PC1 that integrates both variables. Exposure to LINALOOL or CLAIGEION suppressed the increase in PC1 value during fatigue loading (Fig. 9). We also investigated the correlation (Pearson) between these five fatigue indices (adrenaline, noradrenaline, dopamine, d-ROMs, and BAP). Although some combinations of adrenaline and noradrenaline showed high correlation coefficients, this was due to high values in only one individual. On the other hand, dopamine showed a significant correlation with d-ROMs, whereas BAP showed no significant correlation, although the above principal component analysis clearly showed that it was related to d-ROMs via the principal components. Therefore, we performed a principal component analysis of the three factors excluding adrenaline and noradrenaline (Fig. 10, left panel of Fig. 11). As a result, one principal component was extracted from the three factors, and its score significantly increased during fatigue loading and decreased with exposure to LINALOOL or CLAIGEON (Figure 11, right). Therefore, the fatigue suppression (reduction) effect of LINALOOL and CLAIGEON was confirmed.
[0058] (Serum cytokine concentrations) The concentrations of IL-1α, IL-4, IL-1β, IL-2, IL-6, IL-10, IFNγ, IL-5, IL-17A and TNFα in serum were measured using Luminex. Of these, many of the values for IL-1α, IL-4, IL-6, IFNγ and TNFα were below the measurement limit. Therefore, for IL-1β, IL-2, IL-10, IL-5 and IL-17A, those values below the measurement limit were set to 1 / 10 of the detection limit and analyzed. The results are shown in Table 6 and Figure 12. IL-1β and IL-10 both increased with fatigue, and the increase tended to be suppressed by exposure to LINALOOL (LIN) or CLAIGEON (CLG). On the other hand, IL-2 and IL-5 tended to decrease with fatigue, and the decrease was suppressed by exposure to LINALOOL or CLAIGEON. In addition, the concentration of IL-17A was also confirmed to decrease with fatigue, and was restored by exposure to CLAIGEON and LINALOOL (Figure 12). The correlation between the concentrations of these five cytokines was examined. IL-1β showed a positive correlation with IL-10, and IL-2, IL-5, and IL-10 (Figure 13). Principal component analysis was performed on the five factors of these serum cytokine concentrations, and two principal components were extracted. IL-2, IL-5, and IL-17A contributed positively to the first principal component PC1 (contribution rate 61.008%), while IL-10 and IL-1β contributed negatively (see factor loading plot in Figure 13). The score of PC1 was significantly decreased by fatigue load, and the decrease was significantly suppressed by exposure to LINALOOL or CLAIGEON (Figure 14, top). On the other hand, the score of the second principal component PC2 (contribution rate 32.130%) showed no difference between the groups (Figure 14, bottom right). Therefore, the effects of LINALOOL and CLAIGEON in inhibiting an increase in IL-1β, a decrease in IL-2, an increase in IL-10, a decrease in IL-5, and a decrease in IL-17A were confirmed.
[0059] [Table 6]
[0060] (leukocyte mRNA expression) Leukocyte mRNA for IL-1β, IL-6, TNFα, CD14, and CD16 were measured by qPCR.
[0061] IL-1β The results are shown in Table 7 and FIG. Regarding IL-1β mRNA expression, there was a tendency for expression to be suppressed in both the LINALOOL exposure group and the CLAIGEON exposure group compared to the load / no fragrance (no exposure) group. The water immersion stress / no fragrance group had increased IL-1β mRNA expression compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had lower IL-1β mRNA expression compared to the fragrance-free group. The LINALOOL exposure group and the CLAIGEON exposure group, compared to the fragrance-free group, suppressed the increase in IL-1β mRNA expression in the loaded group relative to the unloaded group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on IL-1β expression was confirmed.
[0062] IL-6 The results are shown in Table 8 and FIG. The water immersion stress / no fragrance group showed no change in IL-6 mRNA expression compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had higher IL-6 mRNA expression than the fragrance-free group. The LINALOOL and CLAIGEON exposure groups each promoted an increase in IL-6 mRNA expression in the loaded group versus the unloaded group, compared to the fragrance-free group. Therefore, the effect of LINALOOL and CLAIGEON in promoting IL-6 expression was confirmed.
[0063] TNFα The results are shown in Table 9 and FIG. Regarding TNFα mRNA expression, there was a tendency for expression to be suppressed in the CLAIGEON exposure group compared to the load / no fragrance (no exposure) group. The water immersion stress / no fragrance group had increased TNFα mRNA expression compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed group and the CLAIGEON-exposed group, both with and without water immersion stress, had lower TNFα mRNA expression compared to the fragrance-free group. The LINALOOL exposure group and the CLAIGEON exposure group, compared to the fragrance-free group, suppressed the increase in TNFα mRNA expression in the loaded group relative to the unloaded group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on TNFα expression was confirmed.
[0064] CD14 The results are shown in Table 10 and FIG. The water immersion stress / no fragrance group had increased CD14 mRNA expression compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed and CLAIGEON-exposed groups, both of which were not subjected to water immersion stress, had higher CD14 mRNA expression than the non-fragranced group. The LINALOOL-exposed and CLAIGEON-exposed groups, which were subjected to water immersion stress, had lower CD14 mRNA expression than the non-fragrance group. The LINALOOL exposure group and the CLAIGEON exposure group, compared to the fragrance-free group, suppressed the increase in CD14 mRNA expression in the loaded group relative to the unloaded group. Therefore, the effects of LINALOOL and CLAIGEON in regulating and suppressing CD14 expression were confirmed.
[0065] CD16 The results are shown in Table 11 and FIG. Regarding CD16 mRNA expression, there was a tendency for expression to be suppressed in the LINALOOL-exposed group and the CLAIGEON-exposed group compared to the fragrance-free (non-exposed) group among the loaded groups. The water immersion stress / no fragrance group had increased CD16 mRNA expression compared to the no water immersion stress / no fragrance group. The LINALOOL-exposed and CLAIGEON-exposed groups, which were subjected to water immersion stress, had lower CD16 mRNA expression than the non-fragrance group. The LINALOOL exposure group and the CLAIGEON exposure group each suppressed the increase in CD16 mRNA expression in the loaded group relative to the unloaded group, compared to the fragrance-free group. Therefore, the inhibitory effect of LINALOOL and CLAIGEON on CD16 expression was confirmed.
[0066] [Table 7] (Relative value with one sample without load / exposure set as 1)
[0067] [Table 8] (Relative value with one sample without load / exposure set as 1)
[0068] [Table 9] (Relative value with one sample without load / exposure set as 1)
[0069] [Table 10] (Relative value with one sample without load / exposure set as 1)
[0070] [Table 11] (Relative value with one sample without load / exposure set as 1)
[0071] (Comprehensive analysis: Calculation of fatigue and immunity scores using principal component analysis) A comprehensive principal component analysis was performed using 10 factors, including the three fatigue factors (dopamine, d-ROMs, BAP) and the five serum cytokine factors (IL-1β, IL-10, IL-2, IL-5, IL-17A), plus the two factors IL-1β mRNA in leukocytes and TNFα mRNA in leukocytes, which showed a tendency to decrease with fragrance exposure, and an attempt was made to calculate fatigue and immunity scores as principal components extracted. Three principal components were extracted, of which the first principal component (PC1, contribution rate 47.865%) was a component to which dopamine, d-ROMs, BAP, IL-1β mRNA in leukocytes, TNFα mRNA in leukocytes, IL-1β in serum, and IL-10 in serum contributed positively, and the score was significantly increased by fatigue load, and the increase was suppressed by exposure to LINALOOL or CLAIGEON, with the degree of suppression being CLAIGEON>LINALOOL (Figure 20, top). The other principal components, the second principal component (PC2) and the third principal component (PC3), showed no differences between the groups (Figure 20, bottom right). Therefore, the fatigue / stress suppressing, anti-inflammatory and immunosuppressive effects of LINALOOL and CLAIGEON were confirmed. On the other hand, when principal component analysis was performed on all measurement items (16 factors) other than cytokines, many of which were below the measurement limit, four principal components were extracted, but the PC1 score did not show significant differences between the groups (Figure 21, upper left). On the other hand, the results of the cluster analysis supported the results of the principal component analysis in Figure 21, clearly showing a tendency for fatigue to increase IL-1β mRNA, TNFα mRNA, d-ROMs, and BAP, and to decrease IL-2, IL-5, and IL-17A concentrations (Figure 21, bottom left). Furthermore, in order to eliminate the unique characteristics of specimen #10 (one individual in the stressed / no fragrance group), we performed principal component analysis using eight factors excluding IL-1β and IL-10. The score of the extracted first component, PC1 (contribution rate 53.922%), was significantly increased by fatigue, the increase tended to be suppressed by exposure to LINALOOL, and the increase was significantly suppressed by exposure to CLAIGEON (Figure 21, right).
[0072] The results of Example 1 confirmed that body weight, dopamine, adrenaline, noradrenaline, d-ROMs, BAP, IL-1β mRNA, TNFα mRNA, CD14 mRNA, CD16 mRNA, IL-1β, IL-2, IL-5, IL-10, and IL-17A were effective as fatigue markers, and that IL-1β, TNFα mRNA, IL-1β mRNA, IL-10, CD14 mRNA, and CD16 mRNA were effective as inflammation markers. EXAMPLES
[0073] (Evaluation of anti-fatigue effect by exposure to CLAIGEON) Fatigue model rats were exposed to fragrance substances and fatigue markers were measured, and differences in responses were evaluated by varying the concentration of CLAIGEON. We varied the concentration of CLAIGEON and measured fatigue markers in fatigue model rats to evaluate the difference in response. Water intake and leukocyte mRNA expression (IL-1β) were evaluated.
[0074] (Laboratory animals and fragrances used) Twenty-one 7-week-old male Sprague-Dawley rats (all fatigued [5 rats without fragrance, 4 rats with solvent only (carrier), 4 rats with CLAIGEON concentrations of 0.5%, 4 rats with 20%, and 4 rats with 100% (total of 5 groups)]) were used.
[0075] (Measurement items) Water consumption, leukocyte mRNA expression (IL-1β)
[0076] (Test group) The following groups were tested: Water immersion stress / no fragrance group (5 animals) Water immersion stress / solvent exposure group (4 animals) Water immersion stress / 0.5% CLAIGEON exposure group (4 animals) Water immersion stress / 20% CLAIGEON exposure group (4 animals) Water immersion stress / 100% CLAIGEON exposure group (4 animals)
[0077] (Fragrance exposure) The fragrance used was CLAIGEON (methyl dihydrojasmonate). For the rats in the CLAIGEON exposure group, 1 g of 0.5% CLAIGEON, 20% CLAIGEON or 100% CLAIGEON was weighed out and soaked into filter paper, which was then placed on a glass petri dish, and the glass petri dish was then placed in a corner of the fragrance exposure box shown in Figure 1. The fragrance exposure box had air holes only on the front and back, and the air holes on the sides were blocked with tape (the air holes on the sides were opened if the rats appeared to be having difficulty breathing). The fragrance exposure was for 24 hours. Rats in the fragrance-free group were housed for 24 hours in a box under the same conditions except that it did not contain the glass dish containing the fragrance.
[0078] (Fatigue Loading and Sample Collection Method) All groups were housed in 1.5 cm (23° C.) water-immersed cages for 24 hours to deprive the rats of rest and sleep. The rats were housed one per cage. They were allowed to drink water and eat food ad libitum during the feeding period (Fig. 1, Fig. 2). The weight of the rats, the mass of food, and the mass of drinking water were measured over time (0 and 24 hours). 24 hours after the start of the load, the rats were anesthetized with 4% sevoflurane and blood samples were taken from the heart.
[0079] (Sample separation) After water immersion stress, blood was collected from each rat, and leukocytes, serum, and plasma were separated. White blood cells were prepared by mixing 2 mL of blood (containing 5 mM EDTA) with an aqueous dextran solution (final concentration 1.5%), precipitating the red blood cell components, collecting the white blood cell fraction from the supernatant, and removing excess red blood cells by hemolysis to obtain the white blood cell sample. After that, first strand DNA was prepared and then frozen and stored. Plasma was prepared by centrifuging 2 mL of blood (containing 5 mM EDTA) at 3000 rpm for 10 minutes at room temperature, and the supernatant was used as plasma. It was immediately frozen at -70°C. After collecting approximately 5 mL of blood (without EDTA), serum was left to stand for 30 minutes or more (within 100 minutes) to allow blood coagulation and fibrinolysis, and then centrifuged twice at 3,000 rpm for 10 minutes at room temperature, and the supernatant was collected.
[0080] (Real-time PCR) Total RNA was isolated from white blood cells using an RNeasy kit (QIAGEN). First strand DNA was synthesized from the isolated RNA using ReverTraAce qPCR RT master mix (TOYOBO) and frozen and stored at -30°C. The next day, real-time PCR was performed using SYBR green mix (Thermo Fisher Scientific). The instrument used was Step OnePlus (Thermo Fisher Scientific). The primers used are shown in Table 12.
[0081] [Table 12]
[0082] Water consumption The results are shown in Table 13 and FIG. A trend towards decreased water intake was observed in the CLAIGEON-exposed group. Therefore, the effect of CLAIGEON in suppressing water intake was confirmed.
[0083] [Table 13]
[0084] IL-1β The results are shown in Table 14 and FIG. Compared to the vehicle-exposed group, IL-1β mRNA expression was lower in the 20% CLAIGEON-exposed group and the 100% CLAIGEON-exposed group. Therefore, the inhibitory effect of CLAIGEON on IL-1β expression was confirmed even at these concentrations.
[0085] [Table 14] (Relative value with the unscented sample set at 1) EXAMPLES
[0086] Based on the fatigue load and recovery conditions in Examples 1 and 2, principal component analysis (PCA) was performed using the measurement results in Example 1 for nine items, namely dopamine, IL-1β mRNA, TNFα mRNA, d-ROMs, BAP, IL-2, IL-5, IL-1β, and IL-10, and six items, namely dopamine, IL-1β mRNA, d-ROMs, BAP, IL-2, and IL-5. As a result, for both 9 and 6 items, the scores of the first principal component (PC1) significantly increased with fatigue load, and the increase was inhibited by exposure to LINALOOL or CLAIGEON, with the degree of inhibition being CLAIGEON > LINALOOL (Figures 24 and 25). In particular, the significant difference in the intergroup comparison of the scores of the 6-item PCA was similar to that of the 10-item fatigue and immunity score in Example 1, but the contribution rate of PC1 was 56.871%, which was higher than that of the 10-item PCA (10-item PC1: 47.865%) and the 9-item PCA (9-item PC1: 48.303%, Figure 24) (Figure 25). Since these six items are related to dopamine in neuroendocrine, IL-1β mRNA in inflammation, d-ROMs and BAP in oxidative stress, and IL-2 and IL-5 in immune function, they can also be used as new indicators covering neuroendocrine, inflammation, oxidative stress, and immune function.
[0087] (General Introduction) a. Body weight change Overall, there was a tendency for an increase in the no-load group and a tendency for a decrease in the load group, which was reasonable and the reproducibility from the preliminary experiment was observed. Among the load groups, weight loss was suppressed in the LINALOOL exposure group and the CLAIGEON exposure group. It was found that CLAIGEON had a higher effect on suppressing weight loss than LINALOOL. Since body weight is also related to food intake, it is considered that there are also differences in food intake. b. Serum d-ROMs / BAP There was a tendency for suppression in the CLAIGEON exposure group for both d-ROMs and BAP. c. Plasma catecholamine three fractions For adrenaline and noradrenaline, there was a tendency for suppression in the LINALOOL exposure group and the CLAIGEON exposure group. It can be said that the strength of suppression was LINALOOL < CLAIGEON. The inhibitory effect was also observed in the no-load group, and it was found that there was a dopamine inhibitory effect even at rest. d. Principal component analysis of fatigue indicators When principal component PC1 was extracted from d-ROMs and BAP using principal component analysis and the inter-group comparison was examined, it was found that there was a difference in the PC1 value between the no-spice group and the CLAIGEON exposure group among the fatigue load groups. This indicates that CLAIGEON exposure acts on the attenuation of the fatigue level measured from both values. Furthermore, the score of the principal component extracted by principal component analysis of the three factors including dopamine, which also showed a spice exposure effect alone, increased towards the fatigue load, and the increase in the score was suppressed only by CLAIGEON exposure. From this, the fatigue-reducing effect of CLAIGEION can also be grasped. e. Inter-group comparison and principal component analysis of cytokine concentrations in serum Concentrations of IL-1β and IL-10, which contribute to inflammation, increased with fatigue, and there was a tendency for these increases to be suppressed by fragrance exposure. On the other hand, IL-2, which acts on NK cell activation and T cell proliferation, and IL-5, which acts on antibody production (especially IgA production), decreased or tended to decrease with fatigue, and fragrance exposure suppressed the decrease in both. These characteristics were clearly shown as the first component PC1 of the principal component analysis, and therefore it was revealed that the measurement of multiple serum cytokine concentrations is an effective method for determining the degree of fatigue. f. mRNA expression in peripheral blood leukocytes In the loaded groups, expression of inflammatory markers such as IL-1β and TNFα was suppressed in the LINALOOL and CLAIGEON exposure groups. g. Overall analysis and conclusions Principal component analysis of 10 factors, including three fatigue factors (dopamine, d-ROMs, BAP) and five serum cytokine factors (IL-1β, IL-10, IL-2, IL-5, IL-17A), plus two factors in leukocytes, IL-1βmRNA and TNFαmRNA, which showed a tendency to decrease with fragrance exposure, clearly showed the characteristics of fatigue load as the first component PC1. Dopamine, d-ROMs, and BAP can be understood as indicators of fatigue and stress, while TNFα mRNA, IL-1β, and IL-10 concentrations can be understood as indicators of inflammation. The PC1 score is an indicator of fatigue aggravation to which these factors contribute, while the negative contribution of IL-2, IL-5, and IL-17A, which are indicators of immune function, indicates that a decrease in PC1 score implies a decrease in immune function. The results of the cluster analysis clearly showed the characteristics of the effects of fatigue load, and the score based on eight factors excluding IL-1β and IL-10 concentrations showed similar results. From the above, it can be said that the index, which can be called a "fatigue-immunity score" based on these 10 or 8 factors, is a poor indicator that encompasses fatigue, stress, inflammation, and immune function, and exposure to LINALOOL or CLAIGEON was able to improve this poor condition. It is thought that fatigue load induces an inflammatory response, and that exposure to the fragrance improved the resulting temporary decline in immune function. This suggests the possibility of health promotion and disease prevention based on the mechanism of fatigue improvement by fragrance exposure. [Industrial Applicability]
[0088] A novel agent comprising methyl dihydrojasmonate or 3,7-dimethyl-1,6-octadien-3-ol can be provided.
Claims
1. A sleep-deprivation fatigue suppressant that contains methyl dihydrojasmonate.
2. A fatigue suppressant as described in claim 1, which has a fatigue suppressing effect by increasing appetite during fatigue.
3. The fatigue inhibitor according to claim 1, which has a fatigue inhibitory effect by suppressing increases in d-ROMs, BAP, adrenaline, noradrenaline, and dopamine.
4. A fatigue inhibitor of claim 1, which has a fatigue inhibitory effect by suppressing an increase in IL-1β in serum, suppressing a decrease in IL-2 in serum, suppressing an increase in IL-10 in serum, suppressing a decrease in IL-5 in serum, and suppressing a decrease in IL-17A in serum.
5. The fatigue suppressant of claim 1, which has a fatigue suppressing effect by suppressing an increase in d-ROMs, an increase in BAP, an increase in adrenaline, an increase in noradrenaline, an increase in dopamine, an increase in serum IL-1β, a decrease in serum IL-2, an increase in serum IL-10, a decrease in serum IL-5, and a decrease in serum IL-17A.
6. A fatigue inhibitor as described in claim 5, having the effect of improving decreased immune function caused by fatigue.
Citation Information
Patent Citations
Mitigator of premenstrual and / or intermenstrual, physical and / or mental unpleasantness
JP2006256996A
Arachidonic acid metabolism inhibitor
JP2007169245A
Cosmetic composition or food and drink composition
JP2018203628A
White tea-like flavor composition for perfumery
JP2020012022A
Use of jasmonate for improving skeletal muscle function
WO2012079057A2
